United States Drug Patent 8,759,351: Claim Scope, Aripiprazole Injection Coverage, and Patent Landscape

US Patent No. 8,759,351 covers an extended-release injectable suspension of aripiprazole that does not use a sustained-release matrix. Its central technical limitations are a minimum aripiprazole concentration of approximately 10 mg/mL, administration by injection, and aripiprazole exposure lasting at least 21 days. The patent is directed to long-acting injectable aripiprazole products such as Abilify Maintena rather than oral aripiprazole or aripiprazole lauroxil products such as Aristada.

The patent has an estimated statutory expiration date of February 27, 2029, based on its earliest claimed priority date. The precise enforceability date depends on the USPTO patent-term-adjustment record and any terminal disclaimer or post-grant changes. The patent is listed in the FDA Orange Book for Abilify Maintena. [1][2]

What does US Patent 8,759,351 protect?

US 8,759,351 protects two related categories:

An injectable composition containing suspended aripiprazole at a concentration of at least approximately 10 mg/mL, without a sustained-release matrix, that provides release for at least 21 days.
A method of administering that composition so that a therapeutically effective amount of aripiprazole remains in plasma for at least approximately 21 days.

The patent therefore combines formulation limitations with pharmacokinetic performance limitations. A competing product must satisfy each required limitation of at least one asserted claim to infringe.

Claim	Protected subject matter	Main limitations
Claim 1	Injectable composition	Aripiprazole suspension; at least about 10 mg/mL; injection vehicle; optional viscosity-enhancing agent; no sustained-release matrix; release for at least 21 days
Claim 2	Treatment method	Administration of the composition; no sustained-release matrix; at least about 10 mg/mL aripiprazole; therapeutically effective plasma amount for at least about 21 days

The claims do not require a particular commercial brand, dose strength, vial size, particle-size distribution, excipient, manufacturing process, or injection interval. Those limitations may appear in the specification, dependent claims, related patents, product labeling, or prosecution history, but they are not express limitations of the two claims quoted in the request.

How should claim 1 of US 8,759,351 be construed?

Claim 1 is a composition claim with six material elements.

1. Injectable composition

The product must be suitable for injection. A product designed only for oral, transdermal, inhaled, or implanted delivery would fall outside the literal scope of this limitation.

The claim does not specify intramuscular versus subcutaneous administration. A competing injectable suspension may therefore face risk even if it uses a different injection site, subject to claim construction and the patent’s prosecution history.

2. Suspension of aripiprazole

Aripiprazole must be present as suspended material rather than solely as a fully dissolved solution. This limitation is important because it points toward a depot formed by poorly soluble aripiprazole particles at the injection site.

A formulation containing aripiprazole in a dissolved state without suspended drug would present a noninfringement position. That position could weaken if the commercial formulation contains any suspended aripiprazole or if the asserted claim is applied under the doctrine of equivalents.

3. At least about 10 mg/mL

The claim requires an aripiprazole concentration of at least approximately 10 mg/mL. The term “about” introduces a tolerance that is determined from the patent specification, prosecution record, technical context, and ordinary meaning.

The threshold is commercially significant. A low-concentration injectable product may avoid literal infringement, but it would need to establish that its actual concentration is outside the legally relevant range. Concentration should be assessed in the claimed injection composition, not automatically by reference to the mass of drug in a vial before reconstitution.

4. Injection vehicle

The suspension must include an injection vehicle. The claim does not limit the vehicle to water or to the excipient system used by Abilify Maintena. A different aqueous vehicle, buffer, tonicity agent, or excipient combination may still meet this limitation.

5. Optional viscosity-enhancing agent

The viscosity-enhancing agent is expressly optional. Its absence does not avoid the claim. If present, a polymer or other viscosity modifier may support infringement, but the claimant does not need to prove that the accused product contains one.

This drafting choice gives the claim broader coverage than a formulation claim that requires a named polymer such as carboxymethylcellulose.

6. No sustained-release matrix

The composition must be free of sustained-release matrices. This is a key boundary of the patent.

The claim is directed to extended release produced by the suspended aripiprazole formulation itself, rather than by embedding the drug in a polymeric implant, microsphere, lipid matrix, or other sustained-release carrier. A formulation using a polymer matrix as the release-controlling structure may have a noninfringement argument, although the result would depend on the meaning of “sustained release matrix” and the actual role of the excipient.

The limitation does not necessarily exclude every polymer. A viscosity-enhancing polymer may be present because the claim expressly allows one. The relevant question is whether the formulation contains a sustained-release matrix, not merely whether it contains a polymer.

7. Release for at least 21 days

The claim requires aripiprazole release for at least 21 days. This limitation distinguishes the invention from conventional immediate-release injectable products.

The patent does not require monthly administration. A product releasing aripiprazole for 21 days, 28 days, 56 days, or longer could potentially fall within the claim if all other elements are met.

How should claim 2 of US 8,759,351 be construed?

Claim 2 is a method-of-treatment claim. It requires actual administration of the claimed type of formulation and a resulting plasma exposure.

The principal differences from claim 1 are:

Claim 2 requires a method of providing aripiprazole to an individual.
It requires administration of the formulation.
It requires a therapeutically effective amount in plasma for at least approximately 21 days.
It does not merely require that the product be capable of releasing aripiprazole for 21 days.

A manufacturer may directly infringe claim 1 by making, using, selling, offering to sell, or importing an infringing composition. Direct infringement of claim 2 generally requires performance of the administration method. Commercial labeling, instructions, inducement, and the identity of the actor administering the product become important to method-claim enforcement under 35 U.S.C. §§ 271(a) and 271(b).

What is the difference between “release for 21 days” and “plasma for 21 days”?

The two limitations address different evidence.

Issue	Claim 1	Claim 2
Primary evidence	In vitro release data, in vivo release data, formulation performance	Pharmacokinetic and clinical plasma-concentration data
Required result	Aripiprazole release for at least 21 days	Therapeutically effective plasma amount for at least 21 days
Product focus	Composition	Administration and patient exposure
Main dispute	What constitutes release, and how it is measured	What constitutes therapeutic effectiveness and whether plasma levels meet it

A formulation may release drug for 21 days without maintaining a therapeutically effective plasma level for the same period. Conversely, a formulation may generate prolonged plasma exposure through pharmacokinetic effects not fully captured by a simple in vitro release test.

That distinction creates separate invalidity and noninfringement issues. A challenger may attack the breadth or definiteness of the 21-day limitation, the support for the claimed performance, or the relationship between the claimed composition and the measured pharmacokinetic outcome.

What drug products are most relevant to US 8,759,351?

Abilify Maintena

Abilify Maintena is an extended-release injectable suspension of aripiprazole monohydrate developed by Otsuka Pharmaceutical Co., Ltd. and marketed in the United States by Otsuka America Pharmaceutical, Inc. FDA approved the product in 2013 for the treatment of schizophrenia in adults and, later, for maintenance monotherapy treatment of bipolar I disorder. [3]

The product is supplied in 300 mg and 400 mg strengths and is administered by intramuscular injection, generally once monthly. The reconstituted product contains aripiprazole monohydrate suspended in an injection vehicle. The product labeling describes excipients including carboxymethylcellulose sodium, mannitol, sodium phosphate, and water for injection. [3]

The product’s monthly dosing profile closely corresponds to the 21-day duration limitation in US 8,759,351.

Aristada

Aristada is an extended-release injectable suspension of aripiprazole lauroxil, a prodrug of aripiprazole. It is not chemically identical to aripiprazole. The active pharmaceutical ingredient in Aristada is aripiprazole lauroxil, which is converted to aripiprazole after administration. [4]

Because claim 1 recites “aripiprazole” and claim 2 requires administering a mixture of aripiprazole, Aristada is not an automatic literal infringement case. The analysis would depend on whether the claim term is construed to cover the prodrug, whether the formulation contains aripiprazole as claimed, and whether an equivalence theory is legally available.

Aristada is protected by a separate Alkermes patent estate involving aripiprazole lauroxil, particle engineering, prodrug conversion, and long-acting delivery. That estate should be analyzed independently from the Otsuka patents covering aripiprazole monohydrate suspension products.

Abilify Asimtufii

Abilify Asimtufii is a two-month formulation of aripiprazole approved by FDA in 2023. It is an extended-release injectable suspension administered at a two-month interval in appropriate patients. [5]

Its longer dosing interval creates a strong technical overlap with the duration language of US 8,759,351. The product’s commercial protection, however, may depend on later patents and Orange Book listings specific to the two-month product, in addition to the earlier patent covering the underlying extended-release suspension concept.

What is the Orange Book status of US 8,759,351?

US 8,759,351 is listed in the FDA Orange Book for Abilify Maintena. The listing identifies the patent as a drug-product patent associated with the approved injectable suspension. [2]

The Orange Book listing has three practical consequences:

An ANDA applicant seeking approval for a therapeutically equivalent generic version must address the listed patent.
A Paragraph IV certification can trigger patent litigation under the Hatch-Waxman Act.
FDA approval may be delayed by a statutory 30-month stay if the patent holder timely files an infringement action after receiving a Paragraph IV notice.

An Orange Book listing does not establish that every formulation or administration method infringes every claim. It identifies a patent that FDA and the reference-product sponsor associate with the approved product.

Expected regulatory challenge path

A generic applicant for an aripiprazole long-acting injectable would likely need to address:

Pharmaceutical equivalence to the reference listed drug.
Extended-release performance.
Suspension characteristics and particle attributes.
Sterility and container-closure requirements.
Reconstitution performance.
Injection-site tolerability.
Bioequivalence or an alternative showing under FDA’s product-specific requirements.
Listed patents through Paragraph IV, Paragraph III, or a section viii statement where legally available.

Because long-acting injectables can have complex release profiles, an ANDA may face greater development and regulatory barriers than an immediate-release tablet ANDA.

When does US 8,759,351 lose exclusivity?

The estimated patent expiration date is February 27, 2029. That estimate is based on the earliest claimed priority date reported for the patent family and the standard 20-year patent term under 35 U.S.C. § 154. [1][6]

Milestone	Date or status
Earliest claimed priority	February 27, 2009
US patent grant	July 1, 2014
Estimated ordinary expiration	February 27, 2029
Regulatory exclusivity	Separate from patent term; depends on FDA product records
Post-expiration generic entry	Subject to FDA approval, other unexpired patents, and litigation outcomes

Patent expiration is not the same as market entry. A generic applicant may obtain approval before expiration but remain subject to the patent, a court injunction, a settlement restriction, or other Orange Book-listed patents. Conversely, a Paragraph IV challenger may launch before expiration if it prevails, obtains a settlement license, or accepts litigation risk.

How many patents cover Abilify Maintena?

The relevant estate is broader than US 8,759,351. Public Orange Book records and related patent-family records identify additional patents associated with Abilify Maintena and aripiprazole depot formulations. The portfolio has included patents directed to:

Long-acting aripiprazole suspension formulations.
Particle size and morphology.
Reconstitution and injection properties.
Dosage regimens.
Extended-release administration.
Formulation excipients.
Product-specific delivery characteristics.

A representative landscape is set out below.

Patent or family area	Subject matter	Commercial relevance
US 8,759,351	Matrix-free aripiprazole suspension; at least about 10 mg/mL; 21-day release	Core formulation protection
Related Otsuka depot-formulation patents	Injectable aripiprazole suspensions and performance characteristics	Potential secondary barriers
Later Otsuka patents	Longer-interval dosing and product-specific formulation features	Relevant to Asimtufii and lifecycle management
Alkermes aripiprazole lauroxil patents	Prodrug, injectable particles, conversion and release profile	Separate Aristada estate
Earlier oral aripiprazole patents	Composition and treatment of oral Abilify	Largely expired or commercially less relevant to LAI entry

Patent counts should be made by jurisdiction, patent family, and product listing rather than by simply counting every publication. Continuation and divisional applications can create multiple enforceable patents addressing overlapping technical features.

Which companies are likely to challenge the patent?

The most credible challengers are generic injectable manufacturers with sterile-suspension manufacturing capabilities and an established ANDA portfolio. Potential participants in the broader aripiprazole generic market include Teva, Viatris, Sandoz, Hikma, Dr. Reddy’s Laboratories, Amneal, and other companies active in complex injectables.

The existence of a generic aripiprazole tablet does not establish the ability to develop a generic long-acting injectable. The technical and regulatory barriers are materially different.

Public patent records must be reviewed for each company’s actual Paragraph IV filing. A company’s development activity, patent litigation history, or marketing of oral aripiprazole does not by itself prove that it has challenged US 8,759,351.

What patent litigation affects Abilify Maintena?

A Paragraph IV challenge involving the patent would likely create litigation in the U.S. District Court for the District of Delaware or another venue selected under the Hatch-Waxman framework. The case would typically address:

Whether the proposed generic formulation meets the “suspension” limitation.
Whether its concentration is at least approximately 10 mg/mL.
Whether the product is free of a sustained-release matrix.
Whether testing demonstrates at least 21 days of release.
Whether the patent claims are enabled and adequately described.
Whether the claims are anticipated or obvious in view of earlier injectable aripiprazole work.
Whether the method claim is directly or indirectly infringed.

A settlement could permit an agreed future launch date before the latest patent expiration, subject to antitrust and regulatory scrutiny. A settlement may also include a license, manufacturing restrictions, a no-challenge provision, or a carve-out from method-of-use labeling.

No settlement should be inferred from the absence of a public launch. Development delays, FDA review, manufacturing problems, and commercial decisions can produce the same result.

How strong is the patent estate for aripiprazole long-acting injections?

US 8,759,351 is technically significant because it claims the delivery architecture underlying a commercially important product without requiring a particular named excipient or polymer. The claim is strongest where an accused product:

Uses suspended aripiprazole rather than a prodrug.
Has a concentration well above 10 mg/mL.
Is administered by injection.
Delivers drug for at least three weeks.
Does not use a conventional sustained-release matrix.

Its main vulnerabilities are claim construction and validity. The broad functional limitations may invite arguments concerning enablement, written description, indefiniteness, anticipation, and obviousness. The “about 10 mg/mL” and “at least 21 days” language may also generate disputes over measurement methodology and acceptable variability.

The patent is less effective against:

Aripiprazole prodrug formulations.
Products using a true sustained-release matrix.
Injectable products with materially shorter exposure.
Formulations below the legally applicable concentration threshold.
Products that do not contain aripiprazole in suspended form.

These distinctions do not eliminate infringement risk because the doctrine of equivalents and related patents may remain relevant.

What manufacturing and IP barriers exist for generic entry?

The primary barriers are technical rather than chemical.

Sterile suspension manufacturing

The manufacturer must control particle size, crystal form, sedimentation, redispersibility, syringeability, needle compatibility, and dose uniformity. Small changes can affect both release kinetics and injection-site tolerability.

Reconstitution and administration

Abilify Maintena is supplied as a powder requiring reconstitution before administration. A generic product must reproduce or adequately characterize the relevant reconstitution and injection behavior. Differences in diluent, mixing time, viscosity, needle gauge, or sedimentation can affect regulatory comparability.

Pharmacokinetic equivalence

Long-acting injectable products may produce prolonged absorption from the injection site. Conventional single-dose bioequivalence approaches may be difficult where the reference product has a long terminal phase and high interpatient variability.

Layered patent protection

Even if a generic avoids US 8,759,351, it may encounter later patents directed to dose regimens, two-month administration, particle properties, manufacturing processes, or product-specific formulations. Freedom-to-operate analysis must cover the complete patent family, not the single patent number.

How does US 8,759,351 compare with Aristada patents?

Issue	US 8,759,351 and Abilify Maintena	Aristada patent estate
Active ingredient	Aripiprazole, commonly aripiprazole monohydrate	Aripiprazole lauroxil prodrug
Sponsor	Otsuka	Alkermes
Delivery form	Injectable suspension	Injectable suspension
Release mechanism	Matrix-free depot suspension	Prodrug conversion and long-acting particle system
Core claim issue	Suspended aripiprazole at least about 10 mg/mL for at least 21 days	Prodrug composition, particles, conversion and dosing
Biosimilar pathway	Not applicable	Not applicable
Generic pathway	ANDA, subject to listed patents and complex-injectable requirements	ANDA, subject to separate product-specific patents

Neither product is a biologic. Biosimilar approval under the Public Health Service Act is therefore not the relevant pathway. The regulatory route is generally an ANDA or, depending on the proposed product and FDA determination, another abbreviated or full application pathway. [7]

What revenue exposure is associated with the patent?

The commercial exposure is concentrated in Otsuka’s long-acting aripiprazole franchise rather than the entire aripiprazole market. Oral aripiprazole competition began years earlier, so the patent’s principal economic value is its ability to delay or manage generic competition against the injectable products.

Revenue risk depends on:

Whether the patent is the last blocking patent.
Whether later patents cover the same reference product.
The timing of the first ANDA approval.
Whether a first generic receives 180-day exclusivity.
Whether a challenger launches at risk.
The discount and substitution rate after entry.
Whether Abilify Asimtufii shifts patients from monthly to two-month dosing.
Whether the generic can match the reference product’s formulation and administration requirements.

A successful generic launch could cause rapid price erosion in the monthly injectable segment, but conversion to a two-month product and physician concerns regarding injection performance may moderate substitution.

Key Takeaways

US 8,759,351 covers a matrix-free injectable suspension of aripiprazole with at least approximately 10 mg/mL concentration and at least 21 days of release.
Claim 2 separately covers administration that maintains a therapeutically effective plasma amount for at least approximately 21 days.
The patent is closely aligned with Abilify Maintena and is listed in the FDA Orange Book for that product.
The estimated ordinary expiration date is February 27, 2029, subject to the official USPTO term record.
The patent does not automatically cover Aristada because Aristada contains aripiprazole lauroxil, a prodrug.
Generic entry requires more than an aripiprazole API or tablet capability. Sterile suspension manufacturing, pharmacokinetic equivalence, reconstitution, injection performance, and patent clearance are central barriers.
Later Otsuka patents and product-specific patents may remain relevant after a challenger addresses US 8,759,351.
Biosimilar risk is not applicable because aripiprazole products are chemically synthesized small-molecule drugs.

Frequently Asked Questions

Is US 8,759,351 a formulation patent or a method-of-use patent?

It contains both. Claim 1 is a formulation claim. Claim 2 is a method-of-treatment claim requiring administration and sustained therapeutic plasma exposure.

Does the patent cover every injectable aripiprazole product?

No. The product must meet the claim elements, including suspended aripiprazole, the applicable approximately 10 mg/mL threshold, absence of a sustained-release matrix, and at least 21 days of release.

Can a generic avoid the patent by using aripiprazole lauroxil?

Potentially, but not automatically. Aripiprazole lauroxil is a prodrug, and the generic would still need to clear Alkermes patents and satisfy FDA requirements for the proposed product.

Does monthly dosing appear as an express claim limitation?

No. The quoted claims require at least 21 days of release or plasma exposure, not a specific 28-day or monthly dosing schedule.

Will patent expiration guarantee immediate generic Abilify Maintena entry?

No. FDA approval, other unexpired patents, litigation outcomes, settlement terms, manufacturing readiness, and commercial launch decisions can delay entry beyond the expiration of US 8,759,351.

References

United States Patent and Trademark Office. (2014). U.S. Patent No. 8,759,351, aripiprazole depot formulations.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2023). Abilify Maintena prescribing information. Otsuka America Pharmaceutical, Inc.
U.S. Food and Drug Administration. (2023). Aristada prescribing information. Alkermes, Inc.
U.S. Food and Drug Administration. (2023). Abilify Asimtufii prescribing information. Otsuka America Pharmaceutical, Inc.
35 U.S.C. § 154. Patent term.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j); Public Health Service Act, 42 U.S.C. § 262.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	522200	⤷ Start Trial
Australia	2004264886	⤷ Start Trial
Canada	2534997	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,759,351